Should enzalutamide be given concurrently with Sip-T in castration-resistant metastatic prostate cancer?

In the phase 3 trial of sip-T, enzalutamide was not available, and concurrent therapy with anti-androgens was not permitted. In fact, all patients were required to be progressing on ADT and prior therapies to be eligible, and additional anti-cancer therapy beyond the sip-T and concurrent ADT was not permitted concurrently. Patients were allowed to get subsequent therapies for CRPC however, at progression, at the discretion of their treating physician. However, this trial was conducted before enz...

Enzalutamide was still in early development when Sip-T was approved. Currently there isn’t enough data in the randomized setting, to justify the use. It’s a fascinating clinical question, and hopefully during the next couple of years, more data will become available.